Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

par Howell R, Wright AM, Clements JN
Publié 2019

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

par Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich
Publié 2017

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

par Khoury Johad, Andrawus Elias, Bishop Boaz Y., Azzam Zaher S.
Publié 2018

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

par Pearson S, Kietsiriroje N, Ajjan RA
Publié 2019

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

par Nina A. Petunina, Milena Е. Telnova
Publié 2018

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

par Marina Vladimirovna Shestakova
Publié 2010

Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes

par Stelia Ntika, Harshitha Jois, Karin Lång, Christian Olsson, Anders Franco-Cereceda, Hanna M. Björck, Camilla Krizhanovskii
Publié 2021

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

par Knop FK, Hansen K, Knop FK
Publié 2010

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day

par Igor A. Sklyanik, Marina V. Shestakova
Publié 2021

Incretins today: multiple effects and therapeutic potential

par Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov
Publié 2019

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

par Marina V. Shestakova, Ekaterina A. Yudovich
Publié 2017

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

par Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova
Publié 2020

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection

par Elena Nikolaevna Trunina, Nina Alexandrovna Petunina, Svetlana Alekseevna Chorbinskaya
Publié 2011

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

par Ahren B
Publié 2010

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice

par Lee J, Cho YK, Kim HS, Jung CH, Park JY, Lee WJ
Publié 2019

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

par Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Publié 2019

The associations of incretin hormone concentration with gestational diabetes mellitus

par Tatiana V. Saprina, Ekaterina S. Timokhina, Olga K. Goncharevich, Svetlana V. Budeeva, Tatiana S. Prokhorenko, Lyubov A. Tashireva, Nadezhda N. Musina, Irina V. Dronova
Publié 2016

Incretin-based therapy: renal effects

par Anton Ivanovich Korbut, Vadim Valerievich Klimontov
Publié 2016

Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?

par Andrey Alexeevich Aleksandrov
Publié 2011

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

par Li C, Wan L, Luo J, Jiang M, Wang K
Publié 2021